LON:RENX Renalytix (RENX) Share Price, News & Analysis GBX 8.76 -0.24 (-2.64%) As of 11:50 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Renalytix Stock (LON:RENX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Renalytix alerts:Sign Up Key Stats Today's Range 8.50▼ 9.5050-Day Range 5.60▼ 1152-Week Range 5.50▼ 15.50Volume2.91 million shsAverage Volume1.53 million shsMarket Capitalization£35.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com. Read More Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENX Stock News HeadlinesRenalytix (LON:RENX) Stock Price Down 4.9% - Time to Sell?October 14 at 2:11 AM | americanbankingnews.comRenalytix Seeks CE Mark for KidneyIntelX.dkd Amid Growing Global InterestOctober 1, 2025 | msn.comThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds.October 14 at 2:00 AM | Crypto 101 Media (Ad)Renalytix shares slump as revenue guidance revised after Tempus dealSeptember 23, 2025 | lse.co.ukRenalytix Plc Announces £500,000 Retail Offer to Bolster Financial PositionSeptember 22, 2025 | tipranks.comLON:RENX Financials | Renalytix AI plc - Investing.comJuly 20, 2025 | investing.comRENX | Renalytix PLC Annual Income Statement - MarketWatchJune 26, 2025 | marketwatch.comEarnings call transcript: Renalytix AI Q4 2024 misses EPS, revenue beatsMarch 20, 2025 | uk.investing.comSee More Headlines RENX Stock Analysis - Frequently Asked Questions How have RENX shares performed this year? Renalytix's stock was trading at GBX 11 at the start of the year. Since then, RENX stock has decreased by 20.3% and is now trading at GBX 8.76. How were Renalytix's earnings last quarter? Renalytix Plc (LON:RENX) posted its earnings results on Tuesday, October, 1st. The company reported ($31.00) earnings per share (EPS) for the quarter. Renalytix had a negative net margin of 1,191.75% and a positive trailing twelve-month return on equity of 293.20%. How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD). Company Calendar Last Earnings10/01/2024Today10/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:RENX CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£109.93 million Net Margins-1,191.75% Pretax MarginN/A Return on Equity293.20% Return on Assets-93.54% Debt Debt-to-Equity Ratio-72.91 Current Ratio0.24 Quick Ratio2.42 Sales & Book Value Annual Sales£2.37 million Price / Sales14.97 Cash FlowGBX 4.77 per share Price / Cash Flow1.84 Book ValueGBX (10.71) per share Price / Book-0.82Miscellaneous Outstanding Shares405,369,000Free FloatN/AMarket Cap£35.52 million OptionableNot Optionable Beta2.10 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (LON:RENX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.